Global Retirement Partners LLC Grows Stake in United Therapeutics Co. (NASDAQ:UTHR)

Global Retirement Partners LLC raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 38.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596 shares of the biotechnology company’s stock after purchasing an additional 164 shares during the period. Global Retirement Partners LLC’s holdings in United Therapeutics were worth $210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Wealth Enhancement Advisory Services LLC lifted its stake in shares of United Therapeutics by 0.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares during the last quarter. MBM Wealth Consultants LLC raised its holdings in United Therapeutics by 1.9% in the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 41 shares in the last quarter. UMB Bank n.a. lifted its position in shares of United Therapeutics by 4.9% during the fourth quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 51 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares in the last quarter. Finally, Nicollet Investment Management Inc. grew its position in shares of United Therapeutics by 1.1% in the 3rd quarter. Nicollet Investment Management Inc. now owns 5,833 shares of the biotechnology company’s stock worth $2,090,000 after buying an additional 61 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 124,164 shares of company stock valued at $45,278,893 in the last three months. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

UTHR opened at $357.50 on Wednesday. The firm has a fifty day moving average price of $361.95 and a 200 day moving average price of $361.11. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The stock has a market cap of $15.96 billion, a P/E ratio of 15.70, a P/E/G ratio of 0.97 and a beta of 0.57.

Analysts Set New Price Targets

A number of research firms recently commented on UTHR. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, LADENBURG THALM/SH SH upped their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.